Relay Therapeutics, Inc.
About Relay Therapeutics, Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $15.4M
- Net income
- -$276.5M
- Total assets
- $621.3M
- Market cap
- $2.9B
- Operating margin
- -1971.6%
- Net margin
- -1800.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $15.4M
- Operating expenses
- $318.1M
- Operating income
- -$302.7M
- Income tax
- $0
- Net income
- -$276.5M
- EPS (basic)
- $-1.61
- EPS (diluted)
- $-1.61
Balance sheet
- Total assets
- $621.3M
- Current assets
- $578.3M
- Total liabilities
- $54.3M
- Current liabilities
- $25.6M
- Shareholders’ equity
- $567.1M
Cash flow
- Operating cash flow
- -$235.5M
- Investing cash flow
- $192.8M
- Financing cash flow
- $1.6M
- Net cash flow
- -$41.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.9B
- EPS (diluted)
- $-1.61
- Shares outstanding
- 215.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $276.5M in FY2025.
- Revenue declined 49% from FY2021 to FY2025.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Relay Therapeutics, Inc..
Write a review
News about Relay Therapeutics, Inc.
News & sentiment via Polygon.io
